Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by J&P Medical Research Ltd..
Recruitment status was  Not yet recruiting
Sponsor:
Collaborators:
InfectoPharm Arzneimittel und Consilium GmbH
Sandoz GmbH
Information provided by:
J&P Medical Research Ltd.
ClinicalTrials.gov Identifier:
NCT01173575
First received: July 29, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted

July 29, 2010
July 29, 2010
August 2010
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

This project aims to assess the clinical and microbiological efficacy of fosfomycin(FOM) in patients with bacterial infection.

Primary objective:

• To assess clinical and microbiological efficacy of FOM in patients with bacterial infection.

Secondary objectives:

  • To determine the rate and severity of unexpected adverse events.
  • To determine the mean duration of therapy with FOM in patients with bacterial infection.

Study design:

Multi-center, non-interventional study

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Any subject with bacterial infection considered suitable for routine antimicrobial therapy with FOM may be included into this analysis.

Bacterial Infection
Not Provided
Bacterial Infection
All Patients with bacterial infection receiving fosfomycin may be included
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
200
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with bacterial infection receiving FOM for clinical purposes will be included into the analysis.

Exclusion Criteria:

-

Both
Not Provided
No
Contact: Freyja Maria Jüttner-Smolle, Prof., MD +43/ 316 385 ext 3302 freyja.smolle@medunigraz.at
Austria
 
NCT01173575
J&P009SAN/2009
No
Oliver Mauric, J&P Medical Research Ltd.
J&P Medical Research Ltd.
  • InfectoPharm Arzneimittel und Consilium GmbH
  • Sandoz GmbH
Not Provided
J&P Medical Research Ltd.
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP